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Abstract
            Atrial fibrillation occurs in 10 – 15% of patients with hyperthyroidism. Low serum
thyrotropin concentration is an independent risk factor for atrial fibrillation. Thyroid hormone
contributes to arrythmogenic activity by altering the electrophysiological characteristics of atrial
myocytes by shortening the action potential duration, enhancing automaticity and triggered
activity in the pulmonary vein cardio myocytes. Hyperthyroidism results in excess mortality from
increased incidence of circulatory diseases and dysrhythmias. Incidence of cerebral embolism is
more in  hyperthyroid patients with atrial fibrillation, especially in the elderly and anti-
coagulation is indicated in them. Treatment of hyperthyroidism results in conversion to sinus
rhythm in up to two-third of patients. Beta-blockers reduce left ventricular hypertrophy and atrial
and   ventricular   arrhythmias   in   patients   with   hyperthyroidism.   Treatment   of   sub   clinical
hyperthyroidism   is   controversial.   Optimizing   dose   of   thyroxine   treatment   in   those   with
replacement therapy and beta-blockers is useful in exogenous subclinical hyperthyroidism.
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Introduction
            Atrial fibrillation is the most common cardiac arrhythmia other than sinus tachycardia
encountered   in   hyperthyroidism.   Atrial   fibrillation   occurs   in   10-15%   of   patients   with
hyperthyroidism1. It may be the presenting problem in some of them. Higher prevalence occurs
in elderly and in those with other coexisting risk factors for atrial fibrillation. Low serum thyroid
stimulating hormone is an independent risk factor for development of atrial fibrillation2. Atrial
fibrillation in thyrotoxicosis is associated with significant mortality and morbidity resulting from
embolic events3.
               Thyroid hormones exert their cardiovascular effects either directly through nuclear
thyroid receptors or indirectly by influencing sympathoadrenergic system and altering peripheral
vascular resistance. Binding of thyroid hormones to nuclear receptors result in increased gene
transcription of cardiac myocyte proteins4. Thyroid hormones upregulate sarcoplasmic Calcium
ATPase, myosin heavy chain alfa, voltage gated K+ channels, Na+ channels and beta1 adrenergic
receptors5-8.  These  effects result  in  increased  heart rate, systolic  hypertension,  increased
ventricular contractility and cardiac hypertrophy. Changes in electrophysiological characteristics
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of atria result in dysrhythmias, especially atrial fibrillation, in patients with hyperthyroidism9.
Thyroid hormones reduce peripheral vascular resistance10  and increase oxygen demand of
tissues, thus increasing cardiac workload. 
Epidemiology
            Sinus tachycardia is the most common arrhythmia in hyperthyroidism11. Atrial fibrillation
is reported in 10 – 15% of patients with hyperthyroidism. Prevalence increases with age. In the
study by Agner T et al, 25% of hyperthyroid patients older than 60 years had atrial fibrillation
compared to 5% in patients less than 60 years of age12. Patients with toxic nodular goiter had an
increased incidence of atrial fibrillation compared to younger patients with Grave’s disease,
probably due to their increased age. (43% versus 10%). Iwasaki T et al reported that 21% of
patients with Grave’s disease had atrial fibrillation with significant difference between those
above and below 40 years of age (31% versus 0%)13. In a large study by Krahn  et al, overt
hyperthyroidism accounted for <1% of cases of new onset atrial fibrillation. According to these
investigators, although serum thyrotropin should be measured in all patients with new onset atrial
fibrillation to rule out hyperthyroidism, this association is rather uncommon in the absence of
additional   symptoms   and   signs   of   hyperthyroidism14.   However,   13%   of   patients   with
unexplained atrial fibrillation, had biochemical evidence of hyperthyroidism in another report2. 
            Lars Frost et al identified that among 40,628 patients with hyperthyroidism from Danish
National Registry over a 20 year period, 8.3% had atrial fibrillation or flutter within 30 days from
the date of diagnosis. The risk factors for atrial fibrillation in patients with hyperthyroidism were
similar to those in general population like age, male sex, ischemic heart disease, congestive heart
failure and valvular heart disease15.   Hyperthyroidism was associated with excess mortality
compared to general population in a cohort of 7209 hyperthyroid subjects, treated with radio
iodine. Excess mortality was due to circulatory diseases. Both cardiovascular (Standardized
mortality ratio 1.2, 95% CI  1.2 to 1.3; p  <0.001) and cerebrovascular (Standardized mortality
ratio 1.4, 95% CI 1.2 to 1.5, p  <0.001) mortality rates were high in hyperthyroid subjects. The
Standardized mortality ratio for dysrhythmia including atrial fibrillation was 1.8 (95% CI 1.5 to
1.9, p value <0.001)16. In another study, 1762 hyperthyroid women treated with radio iodine were
followed for more than 14 years and there was increased mortality from cardiovascular disease17.
Cardiac arrhythmias, of which atrial fibrillation is most frequent contribute to excess mortality
from cardiovascular and cerebrovascular events by inducing heart failure and predisposing to
embolic events.  
Subclinical Hyperthyroidism and Atrial Fibrillation    
            Sub clinical hyperthyroidism is defined as low serum thyrotropin concentration in an
asymptomatic patient with normal serum T3 and T4 concentration. It has a prevalence of 0.5% to
3.9% in adults18 and 11.8% in elderly19. 
            Auer J et al, studied 23,638 persons and found that atrial fibrillation occurred in 13.8%
patients with overt hyperthyroidism and 12.7% patients with sub clinical hyperthyroidism,
compared to 2.3% in euthyroid. The prevalence of atrial fibrillation in patients with low serum
thyrotropin concentration was 13.3% compared to 2.3% in persons with normal values. The
relative risk of atrial fibrillation in subjects with low serum thyrotropin and normal free T3,T4
values compared to those with normal serum thyrotropin was 5.2. Thus low serum thyrotropin
concentration   is associated with >5 fold higher likelihood for atrial fibrillation with no
significant difference between overt and subclinical hyperthyroidism20. Clark T Sawin et al
followed 2007 patients from the original cohort of Framingham Heart Study, who were older
than 60 years, for 10 years, for development of atrial fibrillation. Subjects with low thyrotropin
(<0.1 mU/L) had 28% incidence of atrial fibrillation, compared with 11% in normal subjects.
The relative risk for development of atrial fibrillation in patients with low thyrotropin was 3.11.
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The subjects who had slightly low serum thyrotropin concentrations (0.1 to 0.4mU/L) also had
higher risk than those with normal concentrations (relative risk 1.6; p=0.05)
               Subclinical hyperthyroidism can be endogenous as occurring in Grave’s disease,
multinodular goiter or autonomous toxic nodules or exogenous due to thyroxine therapy.
Exogenous   subclinical   hyperthyroidism   is   the   most   common   cause   of   subclinical
hyperthyroidism21. Subclinical hyperthyroidism is also associated with increased cardiovascular
morbidity and mortality. 1191 subjects aged over 60 years, when followed up for 10 years, those
with low serum thyrotropin (<0.5 mU/L) had higher mortality compared to control population.
This excess mortality resulted mainly from circulatory diseases and supraventricular arrhythmias
including atrial fibrillation also contributed22.
Pathogenesis
            Effects of thyroid hormones on ion currents of atrial myocytes contribute to genesis of
atrial fibrillation. Hyperthyroidism is associated with shortening of action potential duration
(APD) resulting in a substrate for atrial fibrillation . A study on the effects of thyroid hormones
on mRNA expression and currents of major ionic channels in murine atrium showed that T3
increased expression of the Kv1.5 mRNA and decreased L-type Calcium channel mRNA
expression. Action potential duration was shorter in hyperthyroid than in euthyroid myocytes.
The ultra-rapid delayed rectifier potassium currents were considerably increased in hyperthyroid
than in euthyroid myocytes, whereas the transient outward potassium currents were unchanged.
L-type calcium currents were decreased in hyperthyroid than in euthyroid myocytes. T3 increased
the outward currents and decreased the inward currents resulting in reduced action potential
duration23. In another study action potential duration and whole cell currents were studied in
myocytes from left and right atria from control and hyperthyroid mice. Hyperthyroidism resulted
in more significant APD shortening and greater delayed rectifier potassium current increases in
the right atrium than in the left atrium which can contribute to the propensity for atrial
arrhythmias24. Studies using rabbit pulmonary vein cardiomyocytes have shown that thyroid
hormone decreases the APD in pulmonary vein cardiomyocytes which can facilitate the genesis
of reentrant circuits. Incubation with thyroid hormone also increased spontaneous activity in the
pulmonary vein cardiomyocytes similar to the effect on sinoatrial node cells. Thyroid hormone
increased the occurrence of delayed after-depolarisation in pulmonary vein beating and non-
beating   cardiomyocytes.   Incidence   of   early  after-depolarisation   was   increased   in   beating
cardiomyocytes following incubation with thyroid hormone. Thus thyroid hormone may induce
the occurrence of paroxysmal atrial fibrillation through the increase of triggered activity or
automaticity in pulmonary veins25. 
            ECG may be helpful in identifying hyperthyroid subjects at risk for developing atrial
fibrillation. Maximum P wave duration and P wave dispersion were higher in both subclinical
and overt hyperthyroidism. P maximum and P wave dispersion were significant predictors of
paroxysmal atrial fibrillation26.
            Thyroid hormone potentiates the effect of adrenergic system on heart. Catecholamine
levels are either normal or decreased in thyrotoxicosis. Facilitation of action of catecholamines is
by increasing tissue sensitivity by increased transcription of beta adrenergic receptors27  and
structural similarity to catecholamines28. Hyperthyroidism is associated with reduced vagal
activity and reduced heart rate variability which can persist despite restoration of euthyroidism29.
Embolic Events and Anticoagulation
            
            Thyrotoxicosis is complicated by thromboembolism in approximately 15% of cases3.    In
a retrospective study of  610 patients with hyperthyroidism the risk of cerebrovascular events
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was greater in those with atrial fibrillation. 15%  had atrial fibrillation with the highest frequency
in elderly patients. A total of 27 (4.4%) cerebrovascular events occurred, 13% in those having
atrial fibrillation and 3% in those with sinus rhythm. Advanced age rather than the presence of
atrial fibrillation was the important risk factor for embolism. From this study the indication for
prophylactic anticoagulation is doubtful in hyperthyroid patients with atrial fibrillation30. In
younger patients with hyperthyroidism and atrial fibrillation who do not have other heart disease,
hypertension or other risk factors for embolism, the risk of anticoagulant therapy probably
outweighs the benefit31. The risk of embolism in thyrotoxic atrial fibrillation exceeds that of lone
atrial fibrillation. The majority of clinically evident emboli in patients with hyperthyroidism and
atrial fibrillation involves central nervous system  and occur early in the course of the disease32.
Elderly patients with thyrotoxicosis and atrial fibrillation and those with other risk factors for
thromboembolism   have   significantly   increased   risk   for   arterial   thromboembolism   and
anticoagulant treatment is indicated. Elderly patients are particularly at risk for hemorrhagic
complications and hence close monitoring of prothrombin time is required in elderly patients on
warfarin. Antiplatelet agents like aspirin may afford some protection against cardioembolic
stroke in patients with atrial fibrillation, although these are more effectively prevented by
anticoagulation33.
Treatment
               Mainstay of treatment in patients with atrial fibrillation and hyperthyroidism is
restoration of euthyroid status. This is by use of antithyroid drugs like carbimazole, propyl
thiouracil or radio-iodine . Surgery of thyroid gland is done after achieving euthyroid status by
drugs. Beta blockers like propranalol or atenolol are useful in thyrotoxic atrial fibrillation to
reduce heart rate and cardiac failure34,35. Restoration of euthyroid status is frequently associated
with conversion to sinus rhythm . In a study of 163 patients with thyrotoxicosis and atrial
fibrillation, 62% were in sinus rhythm within 8-10 weeks after achieving euthyroid state36. After
3 months only few will revert spontaneously to sinus rhythm. Electrical or pharmacologic
cardioversion may be attempted in patients remaining in atrial fibrillation after achieving
euthyroid status. Rate of reversion to sinus rhythm is less in older patients and in those with
longer duration of atrial fibrillation and structural heart disease. In another study, of the 256
patients who underwent surgery for thyrotoxicosis 23% had preoperative atrial fibrillation. After
surgery 47% of them reverted to sinus rhythm and the rest had better responsiveness to
antiarrhythmic drugs. Restoration of sinus rhythm occurred mostly in patients younger than 50
years while in older patients atrial fibrillation persisted37.
               Treatment of subclinical hyperthyroidism is controversial . Some authors advocate
careful   follow   up   of   these   patients   for   development   of   overt   hypothyroidism,   cardiac
dysrhythmias and other circulatory complications38. But others have suggested routine treatment
for subclinical hyperthyroidism as it is associated with adverse cardiac events. Antithyroid drugs
or radio-iodine may be useful especially in those with nodular goiter and cardiac risk factors39.
Treatment of subclinical hyperthyroidism with antithyroid drugs was shown to reduce left
ventricular mass index, heart rate, atrial and ventricular premature beats and atrial fibrillation.
Many patients in this group with subclinical hyperthyroidism had symptoms, high Wayne clinical
index and echocardiographic abnormalities which reduced with treatment40. Biondi et al
observed that treatment with selective beta1 blocker bisoprolol reduces left ventricular mass
index and atrial arrhythmias in patients taking long term thyrotropin suppressive therapy with
thyroxine41. Dosage of thyroxine in patients receiving replacement therapy should be adjusted to
a normal and not suppressed thyrotropin level42. 
Conclusion
               Atrial fibrillation is a major cause of morbidity and mortality in overt as well as
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subclinical hyperthyroidism. It is associated with cerebral embolic events, especially in elderly
and those with co-morbid risk factors. Treatment with anti-thyroid drugs and beta-blockers is
indicated in most of the cases. 
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